- Home
- JATT vs NRXS Comparison
JATT vs NRXS Comparison
Compare JATT & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | JATT | NRXS |
|---|---|---|
| Founded | 2026 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.9M | 82.0M |
| IPO Year | 2026 | 2023 |
Fundamental Metrics
Financial Performance| Metric | JATT | NRXS |
|---|---|---|
| Price | $10.33 | $5.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 3.9K | ★ 162.9K |
| Earning Date | N/A | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $118.53 |
| Revenue Next Year | N/A | $101.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $10.22 | $2.21 |
| 52 Week High | $23.76 | $9.33 |
Technical Indicators
Market Signals| Indicator | JATT | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 42.43 | 31.79 |
| Support Level | $10.22 | N/A |
| Resistance Level | $10.45 | $7.79 |
| Average True Range (ATR) | 0.11 | 0.54 |
| MACD | 0.07 | -0.18 |
| Stochastic Oscillator | 18.24 | 2.94 |
Price Performance
Historical ComparisonAbout JATT JATT II Acquisition Corp Ordinary Shares
JATT II Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).